Krebs Biochem

Who are the top shareholders of the Krebs Biochem?

The top shareholders of Krebs Biochem are Ipca Laboratories Limited, holding 49.65%, and Sun Pharmaceutical Industries Ltd, the largest public shareholder with 4.81%. Individual investors own 20.42%, while foreign institutional investors hold 0.5%, and there are no mutual funds invested in the company.

The top shareholders of Krebs Biochem include its majority shareholders, who are the promoters. The promoter with the highest holding is Ipca Laboratories Limited, which owns 49.65% of the company. Additionally, Sun Pharmaceutical Industries Ltd is the highest public shareholder, holding 4.81%. Individual investors collectively hold 20.42% of the shares, while foreign institutional investors (FIIs) hold 0.5% through five different FIIs. There are no mutual funds currently invested in Krebs Biochem.

When is the next results date for Krebs Biochem?

No Upcoming Board Meetings

What does Krebs Biochem do?

Krebs Biochemicals & Industries Ltd manufactures Active Pharmaceutical Ingredients (API) through fermentation processes and is classified as a micro-cap company. As of March 2025, it reported net sales of 6 Cr and a net profit of -8 Cr.

Overview:<BR>Krebs Biochemicals & Industries Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (API) through fermentation processes, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 1991 and was formerly known as Krebs Biochemicals Ltd. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 6 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -8 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 207 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.45 <BR>Return on Equity: 18.42% <BR>Price to Book: -1.18 <BR><BR>Contact Details:<BR>Address: Kothapalli(V) Kasimkota(M), Anakapalli Vishakapatnam Andhra Pradesh : 531031 <BR>Tel: 91-040-6680 8040 <BR>Email: investors@kerbsbiochem.com <BR>Website: http://www.krebsbiochem.com

Who are in the management team of Krebs Biochem?

As of March 2023, the management team of Krebs Biochem includes G V L Prasad (Independent Director), R T Ravi (Chairman), Avinash Ravi (Non-Executive Director), Tangirala Malati (Independent Director), Satish Khivsara (Independent Director), Raj Kamal Prasad Verma (Independent Director), Rohit Taparia (Company Secretary & Compliance Officer), and Jitendra Shah (Managing Director). The team features a mix of independent directors and executive roles.

As of March 2023, the management team of Krebs Biochem includes the following individuals:<BR><BR>1. G V L Prasad - Independent Director<BR>2. R T Ravi - Chairman (Non-Executive)<BR>3. Avinash Ravi - Non Executive Director<BR>4. Tangirala Malati - Independent Director<BR>5. Satish Khivsara - Independent Director<BR>6. Raj Kamal Prasad Verma - Independent Director<BR>7. Rohit Taparia - Company Secretary & Compliance Officer<BR>8. Jitendra Shah - Managing Director<BR><BR>This team comprises a mix of independent directors, executive roles, and compliance oversight.

Has Krebs Biochem declared dividend?

No Dividend History Available

Should I buy, sell or hold Krebs Biochem?

What is the technical trend for Krebs Biochem?

As of June 6, 2025, Krebs Biochem's technical trend has shifted to mildly bullish, supported by positive weekly MACD, KST, and Bollinger Bands, although daily moving averages suggest caution.

As of 6 June 2025, the technical trend for Krebs Biochem has changed from mildly bearish to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, supporting the positive shift in sentiment. The Bollinger Bands are also indicating a bullish stance on both weekly and monthly time frames. However, the daily moving averages remain mildly bearish, which suggests some caution. The Dow Theory shows a mixed signal with a mildly bullish weekly stance but a mildly bearish monthly outlook. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Bollinger Bands.

Who are the peers of the Krebs Biochem?

Krebs Biochem's peers include Bafna Pharma, Aarey Drugs, Panch.Organics, Astonea Labs, Auro Labs, Bal Pharma, BDH Industries, Tyche Industries, and Quest Laborato. Auro Labs leads in 1-year returns at 68.93%, while Krebs Biochem has a return of -1.68%.

Peers: The peers of Krebs Biochem are Bafna Pharma., Aarey Drugs, Panch.Organics, Astonea Labs, Auro Labs., Bal Pharma, BDH Industries, Tyche Industries, and Quest Laborato.<BR><BR>Quality Snapshot: Excellent management risk is observed at Auro Labs., BDH Industries, and Tyche Industries, while Average management risk is found at Aarey Drugs, Panch.Organics, Astonea Labs, and Bal Pharma. Below Average management risk is noted for Bafna Pharma. Growth is rated as Good for Bafna Pharma., Astonea Labs, Auro Labs., Bal Pharma, Quest Laborato., and Tyche Industries, while Below Average growth is seen at Aarey Drugs, Panch.Organics, and BDH Industries. Capital Structure is rated as Excellent for Panch.Organics and BDH Industries, Good for Bafna Pharma., Auro Labs., and Tyche Industries, and Below Average for Aarey Drugs, Astonea Labs, Bal Pharma, and Krebs Biochem.<BR><BR>Return Snapshot: Auro Labs. has the highest 1-year return at 68.93%, while Panch.Organics has the lowest at -45.84%. Krebs Biochem's 1-year return of -1.68% is better than Panch.Organics but worse than Auro Labs. Additionally, the six-month returns for Panch.Organics, Bal Pharma, BDH Industries, Tyche Industries, and Krebs Biochem are negative.

How big is Krebs Biochem?

As of 24th July, Krebs Biochemicals & Industries Ltd has a market capitalization of 172.00 Cr and reported Net Sales of 43.32 Cr, with a Net Profit loss of 26.94 Cr over the latest four quarters. Shareholder's Funds were at a loss of 119.22 Cr, while Total Assets were 178.17 Cr.

As of 24th July, Krebs Biochemicals & Industries Ltd has a market capitalization of 172.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 43.32 Cr. However, it experienced a loss of 26.94 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024. Shareholder's Funds were recorded at a loss of 119.22 Cr, while Total Assets amounted to 178.17 Cr.

Are Krebs Biochem latest results good or bad?

Krebs Biochemicals' latest results are concerning, showing a net loss of ₹6.14 crores in Q2 FY26, a 15.41% increase in losses from the previous quarter, and a 67.57% year-on-year revenue decline to ₹4.17 crores. The company faces severe operational challenges and a negative book value, indicating a precarious financial position.

The latest results for Krebs Biochemicals are quite concerning. The company reported a net loss of ₹6.14 crores in Q2 FY26, which is a 15.41% increase in losses compared to the previous quarter. More alarmingly, revenue collapsed by 67.57% year-on-year, dropping to just ₹4.17 crores from ₹12.86 crores in the same quarter last year. This significant decline in revenue indicates severe operational challenges.<BR><BR>Additionally, the operating margin is deeply negative at -66.91%, meaning the company is losing a substantial amount on every rupee of sales. The negative book value of ₹-67.83 per share further highlights the company's precarious financial position, as it suggests that liabilities exceed assets, indicating a state of technical insolvency.<BR><BR>Overall, the results reflect a company in critical distress, with ongoing losses, a collapsing revenue base, and no clear path to recovery. The situation is dire, and without immediate intervention, Krebs Biochemicals faces significant existential risks.

How has been the historical performance of Krebs Biochem?

Krebs Biochem has experienced declining net sales and increasing losses, with total operating income falling from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25, and negative operating profit worsening from -33.99 Cr to -14.32 Cr during the same period. The company's financial health is further indicated by rising total liabilities and deteriorating shareholder equity, resulting in ongoing financial challenges.

Answer:<BR>The historical performance of Krebs Biochem shows a trend of declining net sales and increasing losses over the years.<BR><BR>Breakdown:<BR>Krebs Biochem's net sales decreased from 52.94 Cr in Mar'22 to 43.31 Cr in Mar'25, reflecting a downward trend. Other operating income, which was 6.76 Cr in Mar'22, has dropped to zero by Mar'25, contributing to a total operating income decline from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25. The total expenditure, excluding depreciation, has also decreased from 93.69 Cr in Mar'22 to 58.34 Cr in Mar'25. However, the operating profit (PBDIT) remains negative, worsening from -33.99 Cr in Mar'22 to -14.32 Cr in Mar'25. The profit before tax and profit after tax have shown similar negative trends, with losses increasing from -44.53 Cr and -44.53 Cr in Mar'22 to -26.92 Cr and -26.94 Cr in Mar'25, respectively. The company's total liabilities have increased from 159.22 Cr in Mar'21 to 169.04 Cr in Mar'25, while shareholder's funds have deteriorated, showing a negative value of -146.24 Cr in Mar'25. The cash flow from operating activities has remained negative, indicating ongoing financial challenges. Overall, Krebs Biochem's financial performance has been characterized by declining revenues, increasing losses, and deteriorating equity over the years.

Why is Krebs Biochemicals & Industries Ltd falling/rising?

As of 02-Feb, Krebs Biochemicals & Industries Ltd's stock price has risen to Rs 58.00, reflecting a 2.87% increase after two days of decline. However, the stock has significantly underperformed over the past year and five years, facing ongoing financial challenges despite a short-term uptick in investor interest.

As of 02-Feb, Krebs Biochemicals & Industries Ltd is experiencing a rise in its stock price, currently at Rs 58.00, reflecting an increase of Rs 1.62 or 2.87%. This upward movement comes after two consecutive days of decline, indicating a potential trend reversal. The stock opened today with a significant gain of 9.52%, reaching an intraday high of Rs 61.75. Additionally, the stock has outperformed its sector by 2.94% today, suggesting a positive shift in investor sentiment.<BR><BR>Despite this short-term rise, the stock has faced considerable challenges over the longer term. It has shown a decline of 41.41% over the past year and 50.66% over the last five years, significantly underperforming the benchmark Sensex during these periods. The company has reported negative results for the last four consecutive quarters, with a negative book value and a weak long-term fundamental strength characterized by a high debt-to-equity ratio and declining net sales.<BR><BR>While there is a rise in investor participation, as evidenced by a 22.24% increase in delivery volume on January 30 compared to the five-day average, the overall outlook remains cautious due to the company's ongoing financial struggles. Therefore, while the stock is currently rising, it is essential to consider the broader context of its long-term performance and financial health.

Which are the latest news on Krebs Biochem?